November 23, 2021
Article
In its first real-world study, 2 doses of India’s BBV152 vaccine offered 50% protection against symptomatic COVID-19.
November 20, 2021
Routine infant, child, and adolescent vaccination rates and coverage were lower in 2020 than in 2019, particularly for Black children.
November 19, 2021
Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.
The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.
November 18, 2021
AstraZeneca’s PROVENT and TACKLE stage 3 trials show its vaccine AZD7442 significantly reduced the risk of severe or fatal COVID-19, even among high-risk populations.
November 16, 2021
A new report suggests FDA and CDC deliberations may result in booster doses of the mRNA vaccine becoming available by this weekend.
Previous research suggested vaccine efficacy significantly dips after 6 months, but a new study finds COVID-19 cellular immunity remains strong.
November 15, 2021
Just 39 cases among more than 2.2 million doses administered.
November 11, 2021
2 doses of the India-developed vaccine BBV152 offer 77.8% protection against symptomatic COVID-19 disease.
November 09, 2021
Pfizer-BioNTech's request for the Emergency Use Authorization (EUA) will apply to everyone 18 years and older.
